

Coronavirus can't stop the pharmaceutical location Styria!

Styria confirms its role as a first-class life science location and welcomes the international pharmaceutical company Grey Pharma GmbH.

Graz, 12 May 2020 - In recent years, Styria has developed into one of the most important economic regions in Europe. The region owes its stable R&D rate of over five percent to the high quality and competence of its workforce, which, together with an effective State funding system and intelligent research policy, supports a creative atmosphere for co-operation between industry and science. Companies of all sizes successfully co-operate with universities and research institutions leading to creation of spin-offs, start-ups and competence centres, in an extremely interesting economic dynamic.

Styria as a life science hotbed

The life science sector, i.e. the biological, medical and pharmaceutical sciences, plays a key role here. This young industry is characterised by research-intensive small and medium-sized enterprises which, despite the very risky field of innovation, have a high survival rate in Austria.

The country's unique innovation strategy, with Graz as an important founding driver, is also perceived positively abroad, where it attracts international companies and foreign investors.

This is how Grey Pharma GmbH was founded on May 6th, 2020 adding another innovative pharmaceutical company to the life science location of Styria. For CEO and owner Zahid Hussain it was important from the very beginning to rely on the right partners. RCPE (Research Center Pharmaceutical Engineering GmbH), in close co-operation with PRSG (Pharmaceutical and Regulatory Services GmbH) and BDO Steiermark GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft, has been supporting the entrepreneur from Dubai/UAE in planning and co-ordinating the company settlement since December 2019. The Space One technology park in Graz was selected as Headquarters of the new venture.

Promoting co-operation

The co-operation in the preparation phase with RCPE, PRSG and BDO was unparalleled: "I have never experienced such a professional and friendly co-operation. In every phase,

the Styrian team supported me in the best possible way. Despite the current situation, we have managed to meet the timetable for setting up the company. I am impressed," said Zahid Hussain who, together with his partners, has established several companies in the life science sector worldwide and is co-operating very closely with the World Health Organisation in Africa. "We have already started to build a local team and I can expect to employ around fifteen people by the end of the year". Grey Pharma's business activities include the import, export, manufacture and distribution of innovative pharmaceutical products for and from the European market. RCPE, PRSG and BDO will continue to support the new company in the set-up phase and in the launch of their first product commercialisation, providing their specific expertise: RCPE in the research and development area, PRSG in the drug registration field and BDO for tax and business management issues.

"We are pleased to have again been a leading partner in a further company settlement in Styria and are planning the first joint research projects with Grey Pharma GmbH", the managing directors of RCPE Johannes Khinast and Thomas Klein proudly commented.



Foundation of Grey Pharma GmbH © RCPE GmbH

In this picture, from left to right:

Johannes Khinast - Wissenschaftlicher CEO, Research Center Pharmaceutical Engineering GmbH

Hannes Oberschmid - Senior Manager, BDO Steiermark GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft

Zahid Hussain - CEO und Eigentümer, Grey Pharma GmbH

Lydia Langkammer - CEO und Business Development Senior Regulatory Affairs Manager, Pharmaceutical and Regulatory Services GmbH

Thomas Klein - Wirtschaftlicher CEO, Research Center Pharmaceutical Engineering GmbH

Peter Wenger - Notar, Notariat Pisk&Wenger

TAGS

Austria, Steiermark, Graz, Life-Science, Pharma, RCPE, Grey Pharma, PRSG, BDO, Economy, Growth, Research

The Research Center for Pharmaceutical Engineering (RCPE) is a global leader in pharmaceutical engineering sciences. We help our partners to create and manufacture advanced medicines for patients around the world, through optimising products and processes. RCPE's services encompass the entire value chain of pharmaceutical product development: continuous API synthesis, advanced formulations, next-generation manufacturing, and also device design and optimization.

As a non-profit, private company owned by Graz University of Technology (65%), University of Graz (20%) and JOANNEUM RESEARCH Forschungsgesellschaft mbH (15%), we link outstanding science, application and industry in a business-oriented approach.

RCPE is a K1 COMET Centre within the Competence Centres for Excellent Technologies (COMET) programme. The COMET programme is operated by the Austrian Research Promotion Agency (FFG) on behalf of the Federal Ministry for Climate Protection, Environment, Energy, Mobility, Innovation and Technology (BMK) and the Federal Ministry for Digital and Economic Affairs (BMDW). Our projects are also funded by Land Steiermark and the Styrian Business Development Agency (SFG).

Press contacts:

RCPE GmbH, 8010 Graz, Inffeldgasse 13

Lisa Lepori

Head of Marketing & Public Relations

lisa.lepori@rcpe.at, Tel. +43 664 88418860

Thomas Klein

Business CEO

thomas.klein@rcpe.at, Tel. +43 676 4172363